Chemours
CC | NYSE
$13.58
+$0.05 (+0.37%)
Nov 2, 2026, 10:18 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 5.81B | 5.78B | 6.08B | 6.83B | 6.35B | 4.97B |
Cost of Revenue | 4.91B | 4.63B | 4.77B | 5.22B | 4.96B | 3.9B |
Gross Profit | 902M | 1.15B | 1.31B | 1.62B | 1.38B | 1.07B |
Operating Income | -5M | 443M | -123M | 786M | 674M | 448M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -277M | 127M | -318M | 741M | 676M | 179M |
Net Income | -386M | 86M | -238M | 578M | 608M | 219M |
Selling & General & Admin | 799M | 585M | 1.29B | 710M | 592M | n/a |
Research & Development | 108M | 109M | 108M | 118M | 107M | 93M |
Other Expenses | n/a | 14M | 31M | 2M | 8M | 526M |
Operating Expenses | 907M | 708M | 1.43B | 830M | 707M | 619M |
Interest Expense | 269M | 264M | 208M | 163M | 185M | 210M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 5.81B | 5.34B | 6.2B | 6.05B | 5.67B | 4.52B |
Income Tax Expense | 109M | 41M | -81M | 163M | 68M | -40M |
Shares Outstanding (Basic) | 150.35M | 149.49M | 148.91M | 155.36M | 164.94M | 164.68M |
Shares Outstanding (Diluted) | 150.55M | 150.01M | 148.91M | 158.3M | 168.7M | 166.35M |
EPS (Basic) | -2.57 | 0.58 | -1.60 | 3.72 | 3.69 | 1.33 |
EPS (Diluted) | -2.56 | 0.57 | -1.60 | 3.65 | 3.60 | 1.32 |
EBITDA | 332M | 692M | 197M | 1.2B | 1.18B | 767M |
EBIT | -8M | 391M | -110M | 904M | 861M | 447M |
Depreciation & Amortization | 340M | 301M | 307M | 291M | 317M | 320M |
Add to Watchlist
Select watchlists to add or remove CC